Literature DB >> 9202625

Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus.

F Bortolotti1, M Resti, R Giacchino, C Azzari, N Gussetti, C Crivellaro, C Barbera, F Mannelli, L Zancan, A Bertolini.   

Abstract

OBJECTIVE: To evaluate the clinical, biochemical, and virologic features associated with hepatitis C virus (HCV) infection acquired early in life from mothers with antibodies to HCV (anti-HCV). STUDY
DESIGN: Multicenter prospective-retrospective study in Italian children. PATIENTS: Two groups of children were investigated. Group 1 included 14 infants, born to mothers with anti-HCV but without human immunodeficiency virus infection, who became seropositive for HCV RNA during the first year of life and were thus considered infected. Group 2 included 16 children with chronic hepatitis C, aged 1 1/2 to 14 years, whose mothers were the unique potential source of infection. Both groups were followed for 12 to 48 months.
METHODS: Alanine transaminase (ALT), anti-HCV, and HCV RNA were investigated by the polymerase chain reaction on entry to the study and during follow-up.
RESULTS: All children in group 1 had anti-HCV throughout follow-up, and all had ALT abnormalities, ranging from 1.5 to 10.5 times the normal value during the first 12 months. During further follow-up, 5 of 10 children had HCV RNA with abnormal ALT values, 3 had a return to normal of the ALT values but continued to have viremia, and 2 eventually had normal ALT values and clearance of HCV RNA. Of the 16 children in group 2, all were free of symptoms and 62% had only slight ALT elevations; 7 who underwent liver biopsy had histologic features of minimal or moderate hepatitis.
CONCLUSIONS: HCV infection acquired early in life from mothers with anti-HCV is usually associated with biochemical features of liver damage during the first 12 months of life. Progression to chronicity seems to occur in the majority of cases, although HCV-associated liver disease is likely to be mild throughout infancy and childhood.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202625     DOI: 10.1016/s0022-3476(97)70289-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  7 in total

Review 1.  Hepatitis C in pregnancy.

Authors:  N Hadzić
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

2.  Active surveillance of hepatitis C infection in the UK and Ireland.

Authors:  D M Gibb; P E Neave; P A Tookey; M Ramsay; H Harris; K Balogun; D Goldberg; G Mieli-Vergani; D Kelly
Journal:  Arch Dis Child       Date:  2000-04       Impact factor: 3.791

Review 3.  Perinatal hepatitis C virus infection: diagnosis and management.

Authors:  S M Davison; G Mieli-Vergani; J Sira; D A Kelly
Journal:  Arch Dis Child       Date:  2006-09       Impact factor: 3.791

4.  Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively.

Authors:  Patrizia Farci; Isabella Quinti; Stefania Farci; Harvey J Alter; Rita Strazzera; Elvia Palomba; Alessandra Coiana; Daniele Cao; Anna Maria Casadei; Ritarella Ledda; Raffaele Iorio; Angela Vegnente; Giacomo Diaz; Pier-Angelo Tovo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-17       Impact factor: 11.205

5.  Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection.

Authors:  M Resti; C Azzari; F Mannelli; M Moriondo; E Novembre; M de Martino; A Vierucci
Journal:  BMJ       Date:  1998-08-15

Review 6.  Managing HCV infection in pediatric age group: suggested recommendations.

Authors:  Fazal A Danish; Salman S Koul; Fazal R Subhani; Ahmed E Rabbani; Saeeda Yasmin
Journal:  Saudi J Gastroenterol       Date:  2010 Jul-Sep       Impact factor: 2.485

7.  A used ball of cotton wool as a source of nosocomially-acquired hepatitis C infection.

Authors:  Clement Ibi Mboto; Iquo A Takon; John Ele Ndem
Journal:  Hepat Mon       Date:  2010-03-01       Impact factor: 0.660

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.